{
  "kind": "treatment",
  "slug": "ramelteon-rozerem",
  "type": "medication",
  "name": "Ramelteon (Rozerem)",
  "summary": "Ramelteon, marketed as Rozerem, is a melatonin receptor agonist indicated for the treatment of insomnia characterized by difficulty with sleep onset. It is non-habit-forming and has no evidence of abuse potential.",
  "description": "Ramelteon is a selective melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus of the brain, which are involved in the regulation of circadian rhythms and sleep-wake cycles. Unlike benzodiazepines or Z-drugs, it does not produce sedative or anxiolytic effects via GABA modulation, and it is not associated with withdrawal symptoms or dependence.",
  "category": "medications/sleep-aid",
  "tags": [
    "insomnia",
    "melatonin agonist",
    "sleep onset",
    "non-habit-forming"
  ],
  "metadata": {
    "drug_classes": [
      "Melatonin receptor agonist"
    ],
    "therapeutic_categories": [
      "Sleep medicine"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Rozerem"
    ],
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Sleep medicine",
      "Psychiatry"
    ],
    "fda_approval_year": 2005
  },
  "clinical_metadata": {
    "primary_indications": [
      "Insomnia"
    ],
    "off_label_uses": [
      "Circadian rhythm sleep-wake disorders",
      "Jet lag",
      "Delayed sleep phase disorder"
    ],
    "contraindications": [
      "History of hypersensitivity to ramelteon or any component of the product",
      "Severe hepatic impairment",
      "Concurrent use with fluvoxamine"
    ],
    "monitoring_required": [
      "Liver function tests in patients with suspected hepatic impairment",
      "Monitor for abnormal thinking and behavioral changes",
      "Assess for worsening of depression or suicidal ideation in psychiatric patients"
    ],
    "efficacy_rating": {
      "Insomnia (sleep onset)": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "ramelteon",
      "rozerem",
      "melatonin agonist",
      "sleep onset insomnia"
    ],
    "synonyms": [
      "Ramelteon hydrochloride",
      "MT1/MT2 receptor agonist"
    ],
    "common_misspellings": [
      "ramelton",
      "rameltean",
      "rozeram"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Treatment of insomnia characterized by difficulty falling asleep"
      ]
    },
    {
      "type": "mechanism",
      "text": "Ramelteon selectively binds to MT1 and MT2 receptors in the suprachiasmatic nucleus, which regulate circadian rhythms and the sleep-wake cycle. MT1 receptor activation promotes sleep onset, while MT2 receptor activation shifts circadian rhythm timing."
    },
    {
      "type": "dosing",
      "adult": {
        "Insomnia": "8 mg taken within 30 minutes of going to bed; do not take with or immediately after a high-fat meal."
      }
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 8 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset within 30 minutes; elimination half-life is approximately 1â€“2.6 hours, but receptor binding and circadian modulation effects may persist longer."
    },
    {
      "type": "adverse_effects",
      "common": [
        "dizziness",
        "fatigue",
        "somnolence",
        "nausea"
      ],
      "less_common": [
        "exacerbation of insomnia",
        "hallucinations"
      ],
      "serious": [
        "angioedema",
        "complex sleep behaviors",
        "depression or suicidal ideation"
      ]
    },
    {
      "type": "warnings",
      "other": [
        "Do not use with fluvoxamine due to strong CYP1A2 inhibition",
        "Not recommended in severe hepatic impairment",
        "Potential to exacerbate depression"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Fluvoxamine",
          "risk": "Marked increase in ramelteon exposure",
          "action": "Contraindicated"
        },
        {
          "with": "CYP1A2 inhibitors (e.g., ciprofloxacin)",
          "risk": "Increased ramelteon levels",
          "action": "Monitor closely"
        },
        {
          "with": "CYP3A4 inducers (e.g., rifampin)",
          "risk": "Reduced ramelteon levels",
          "action": "May reduce efficacy"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Assess for improvement in sleep latency",
        "Monitor mood and behavior in psychiatric patients",
        "Liver function in patients with liver disease"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Category C; use only if benefits outweigh risks",
      "lactation": "Unknown if excreted in breast milk; caution advised",
      "geriatrics": "No dosage adjustment required; may be better tolerated than benzodiazepines in older adults"
    },
    {
      "type": "tapering",
      "text": "No tapering required due to lack of withdrawal symptoms or dependence potential."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Does not cause rebound insomnia after discontinuation",
        "May be preferable for patients with history of substance abuse",
        "Avoid high-fat meals before dosing to prevent delayed absorption"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "FDA Prescribing Information - Rozerem",
          "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021782s010lbl.pdf"
        },
        {
          "label": "Drugs.com - Ramelteon",
          "url": "https://www.drugs.com/monograph/ramelteon.html"
        },
        {
          "label": "PubChem - Ramelteon",
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Ramelteon"
        }
      ]
    }
  ],
  "seo": {
    "title": "Ramelteon (Rozerem) - Uses, Dosing, Side Effects, and Safety",
    "description": "Comprehensive guide to ramelteon (Rozerem), a non-habit-forming melatonin receptor agonist for sleep onset insomnia. Learn about uses, dosing, interactions, and safety."
  }
}
